[1] SZAREWSKI A.HPV Vaccination and Cervical Cancer[J].Current Oncology Reports,2012,14(6): 559-567.
[2] CASTLE P E, MAZA M.Prophylactic HPV vaccination: past, present, and future[J]. Epidemiol Infect, 2016, 144(3):449-468.
[3] 李雷,郎景和.人乳头瘤病毒疫苗研究进展[J].中国实用妇科与产科杂志,2017,33(7):769-772.
[4] 吴宝杰,杨志建.HPV及其相关疫苗的研究进展[J].医学综述,2018,24(4):536-538.
[5] 郭建新,李力.HPV与宫颈癌疫苗研究进展[J].中国妇幼健康研究,2004,15(6):395-398.
[6] ALI H, DONOVAN B, WAND H, et al.Genital warts in young Australians five years into national human papillomavirus vaccination programme:national surveillance data[J].BMJ,2013,346: f2032.
[7] MIAO Y X, GAN J M, CHEN J, et al.Clinical significance of human papillomavirus genotyping by gene chip technology in Shanghai[J]. Laboratory Medicine, 2015,30(6):595-598.
[8] BURD E M.Human papillomavirus and cervical cancer[J]. Clin Microbiol Rev, 2003, 16(1):1-7.
[9] SCHELLENBACHER C, RODEN RBS, KIRNBAUER R, et al.Developments in L2-based human papillomavirus (HPV) vaccines[J].Virus Res, 2017, 231(1):166-175.
[10] EGAWA N, EGAWA K, GRIFFIN H, et al.Human papillomaviruses: epithelial tropisms, and the development of neoplasia[J]. Viruses,2015,16(7):3863-3890.
[11] FDA. FDA approves new vaccine for prevention of cervical cancer[EB/OL].(2009-10-16).http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm.
[12] LUCKETT R,FELDMAN S.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer[J].Hum Vaccin Immunother,2016,12(6):1332-1342.
[13] RIETHMULLER D, JACQUARD A C, St GUILY J, et al.Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France[J].BMC Public Health, 2015, 15: 453-459.
[14] HARIRI S, UNGER E R, SCHAFER S, et al.HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States[J].Cancer Epidemiol Biomarkers Prev, 2015,24(2):393-399.
[15] FDA. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV[EB/OL]. (2014-12-10).http://www.americannursetoday.com/fda-approves-gardasil-9-prevention-cancers-caused-additional-types-hpv.FDA.
[16] FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old[EB/OL].(2018-10-05).http://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old.
[17] YANG A, JEANG J, CHENG K, et al.Current state in the development of candidate therapeutic HPV vaccines[J]. Expert Rev Vaccines,2016,15(8): 989-1007.
[18] YANG A, FARMER E, WU T C, et al.Perspectives for therapeutic HPV vaccine development[J]. J Biomed Sci, 2016, 23(1):75.
[19] LEE S J, YANG A, WU T C, et al.Immunotherapy for human papillomavirusassociated disease and cervical cancer: review of clinical and translational research[J]. J Gynecol Oncol, 2016,27(5):e51.
[20] 李响,金文婷,满玉晶,等.HPV疫苗预防宫颈癌的应用研究[J].生殖医学杂志,2017,26(2):188-192.
[21] WHO.Human papillomavirus vaccines:WHO position paper,May 2017-Recommendations[J]. Vaccine, 2017,35(43):5753-5755. |
